One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.
Key findingOne-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hosp
What the researchers found
One-year analysis shows semaglutide reduces total medical costs in obese patients through fewer hospitalizations, ER visits, and complications despite high drug cost.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Semaglutide 2.4 mg once weekly. Costs evaluated excluding pharmacy. Patients had obesity or overweight with ≥1 obesity-related complication.
How the study worked
In publication.
Who was studied
US adults with obesity or overweight and ≥1 obesity-related complication
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
Expert review of pharmacoeconomics & outcomes research, 25(9), 1345-1355
Citation
Arora, Prachi; Michalak, Wojciech; Zhao, Zhenxiang; Fiasconaro, Megan; Hong, Yu; Zhao, Xin; Ó Hartaigh, Bríain; Alvarez, Sara; Fitch, Angela. (2025). Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.. Expert review of pharmacoeconomics & outcomes research, 25(9), 1345-1355. https://doi.org/10.1080/14737167.2025.2570688